(TAK) Takeda Pharmaceutical - Overview
Stock: Oncology, Immunology, Gastroenterology, Rare Diseases, Plasma Therapies
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.48% |
| Yield on Cost 5y | 4.70% |
| Yield CAGR 5y | -2.95% |
| Payout Consistency | 92.3% |
| Payout Ratio | 0.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 18.4% |
| Relative Tail Risk | -2.85% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.45 |
| Alpha | 33.40 |
| Character TTM | |
|---|---|
| Beta | 0.214 |
| Beta Downside | 0.202 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.25% |
| CAGR/Max DD | 0.36 |
Description: TAK Takeda Pharmaceutical January 29, 2026
Takeda Pharmaceutical Co. (NYSE:TAK) is a globally integrated drugmaker that conducts research, development, manufacturing, marketing, and out-licensing of medicines across gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Its branded portfolio includes Entyvio, Velcade, Adcetris, and a suite of plasma products, while the firm maintains a dense network of in-licensing, collaboration, and research agreements with companies such as BioMarin, GSK, Seagen, and Arrowhead to broaden its pipeline.
Key recent metrics (FY 2023 / Q3 2024):
• Consolidated revenue ≈ $31.5 billion, with the gastroenterology franchise contributing ~30% and rare-disease sales up 12% YoY.
• R&D spend ≈ $5.5 billion (≈ 17% of revenue), supporting 13 late-stage candidates, including a next-generation Entyvio biosimilar and novel plasma-derived therapies.
• Net debt-to-EBITDA ratio ≈ 1.8×, reflecting a post-acquisition leverage profile that remains within Takeda’s target range.
These figures sit against broader sector drivers: an aging Japanese population boosting demand for chronic-care drugs, and a sustained 8% CAGR in global biologics sales, which underpins Takeda’s focus on plasma-derived and rare-disease products.
For a deeper quantitative view, see the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 114.75b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.13 > 1.0 |
| NWC/Revenue: 11.29% < 20% (prev 14.33%; Δ -3.04% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1175.85b > Net Income 114.75b |
| Net Debt (4201.25b) to EBITDA (1393.38b): 3.02 < 3 |
| Current Ratio: 1.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.20b) vs 12m ago 1.10% < -2% |
| Gross Margin: 62.11% > 18% (prev 0.65%; Δ 6146 % > 0.5%) |
| Asset Turnover: 29.39% > 50% (prev 30.31%; Δ -0.92% > 0%) |
| Interest Coverage Ratio: 1.97 > 6 (EBITDA TTM 1393.38b / Interest Expense TTM 316.48b) |
Altman Z'' 1.52
| A: 0.03 (Total Current Assets 3118.57b - Total Current Liabilities 2611.96b) / Total Assets 15419.29b |
| B: 0.07 (Retained Earnings 1096.41b / Total Assets 15419.29b) |
| C: 0.04 (EBIT TTM 622.74b / Avg Total Assets 15263.07b) |
| D: 0.77 (Book Value of Equity 5944.22b / Total Liabilities 7769.98b) |
| Altman-Z'' Score: 1.52 = BB |
Beneish M -3.04
| DSRI: 1.05 (Receivables 758.44b/735.06b, Revenue 4486.09b/4579.02b) |
| GMI: 1.05 (GM 62.11% / 65.38%) |
| AQI: 0.97 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 0.98 (Revenue 4486.09b / 4579.02b) |
| TATA: -0.07 (NI 114.75b - CFO 1175.85b) / TA 15419.29b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of TAK shares?
Over the past week, the price has changed by +3.83%, over one month by +13.30%, over three months by +31.16% and over the past year by +37.50%.
Is TAK a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TAK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.9 | 5.6% |
| Analysts Target Price | 18.9 | 5.6% |
| ValueRay Target Price | 19.4 | 8.6% |
TAK Fundamental Data Overview February 01, 2026
P/E Trailing = 74.913
P/E Forward = 11.8483
P/S = 0.0123
P/B = 1.0821
P/EG = 0.3691
Revenue TTM = 4486.09b JPY
EBIT TTM = 622.74b JPY
EBITDA TTM = 1393.38b JPY
Long Term Debt = 4270.17b JPY (from longTermDebt, last quarter)
Short Term Debt = 583.55b JPY (from shortTermDebt, last quarter)
Debt = 4856.63b JPY (from shortLongTermDebtTotal, last quarter)
Net Debt = 4201.25b JPY (from netDebt column, last quarter)
Enterprise Value = 12742.22b JPY (8540.97b + Debt 4856.63b - CCE 655.38b)
Interest Coverage Ratio = 1.97 (Ebit TTM 622.74b / Interest Expense TTM 316.48b)
EV/FCF = 13.32x (Enterprise Value 12742.22b / FCF TTM 956.59b)
FCF Yield = 7.51% (FCF TTM 956.59b / Enterprise Value 12742.22b)
FCF Margin = 21.32% (FCF TTM 956.59b / Revenue TTM 4486.09b)
Net Margin = 2.56% (Net Income TTM 114.75b / Revenue TTM 4486.09b)
Gross Margin = 62.11% ((Revenue TTM 4486.09b - Cost of Revenue TTM 1699.70b) / Revenue TTM)
Gross Margin QoQ = 54.43% (prev 65.85%)
Tobins Q-Ratio = 0.83 (Enterprise Value 12742.22b / Total Assets 15419.29b)
Interest Expense / Debt = 2.59% (Interest Expense 125.86b / Debt 4856.63b)
Taxrate = 22.51% (30.67b / 136.28b)
NOPAT = 482.57b (EBIT 622.74b * (1 - 22.51%))
Current Ratio = 1.19 (Total Current Assets 3118.57b / Total Current Liabilities 2611.96b)
Debt / Equity = 0.64 (Debt 4856.63b / totalStockholderEquity, last quarter 7648.16b)
Debt / EBITDA = 3.02 (Net Debt 4201.25b / EBITDA 1393.38b)
Debt / FCF = 4.39 (Net Debt 4201.25b / FCF TTM 956.59b)
Total Stockholder Equity = 7144.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.75% (Net Income 114.75b / Total Assets 15419.29b)
RoE = 1.61% (Net Income TTM 114.75b / Total Stockholder Equity 7144.80b)
RoCE = 5.46% (EBIT 622.74b / Capital Employed (Equity 7144.80b + L.T.Debt 4270.17b))
RoIC = 4.10% (NOPAT 482.57b / Invested Capital 11773.46b)
WACC = 5.00% (E(8540.97b)/V(13397.61b) * Re(6.70%) + D(4856.63b)/V(13397.61b) * Rd(2.59%) * (1-Tc(0.23)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.12%
[DCF Debug] Terminal Value 85.40% ; FCFF base≈940.79b ; Y1≈860.49b ; Y5≈762.22b
Fair Price DCF = 5946 (EV 22985.81b - Net Debt 4201.25b = Equity 18784.56b / Shares 3.16b; r=5.90% [WACC]; 5y FCF grow -10.67% → 2.90% )
EPS Correlation: 3.53 | EPS CAGR: -0.32% | SUE: -0.00 | # QB: 0
Revenue Correlation: 75.85 | Revenue CAGR: 9.16% | SUE: 0.01 | # QB: 0
EPS next Year (2027-03-31): EPS=109.66 | Chg30d=-12.566 | Revisions Net=-1 | Growth EPS=+114.3% | Growth Revenue=+0.9%